Trial Profile

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alnuctamab (Primary) ; Alnuctamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man
Sponsors Celgene Corporation

Most Recent Events

17 Apr 2025 Status changed from active, no longer recruiting to discontinued, due to changes in business objectives.
19 Feb 2025 Planned End Date changed from 5 Aug 2029 to 18 Mar 2025.
19 Feb 2025 Planned primary completion date changed from 30 Jun 2029 to 18 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com